KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients

BACKGROUND: In this study, we evaluated the possibility that KRAS mutational status might be predictive of oxaliplatin (OXA) efficacy. We also explored the role of excision repair cross complementing group-1 (ERCC-1). METHODS: Ninety anti-epidermal growth factor receptor-naive advanced colorectal ca...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Basso, M, Strippoli, A, Orlandi, A, Martini, M, Calegari, M A, Schinzari, G, Di Salvatore, M, Cenci, T, Cassano, A, Larocca, L M, Barone, C
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2013
Gaiak:
Molecular Diagnostics
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3553525/
https://ncbi.nlm.nih.gov/pubmed/23175150
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.526
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak